Supplementary Materials

Supplementary Material for:

Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis

Alessia Fornoni,* Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada, Alexandra N. Jauregui, Jing Li, Adela Mattiazzi, Gaetano Ciancio, Linda Chen, Gaston Zilleruelo, Carolyn Abitbol, Jayanthi Chandar, Wacheree Seeherunvong, Camillo Ricordi, Masami Ikehata, Maria Pia Rastaldi, Jochen Reiser,* George W. Burke III*

*To whom correspondence should be addressed. E-mail: afornoni{at}med.miami.edu (A.F.); jreiser{at}med.miami.edu (J.R.); gburke{at}med.miami.edu (G.W.B.)

Published 1 June 2011, Sci. Transl. Med. 85ra46 (2011)
DOI: 10.1126/scitranslmed.3002231

This PDF file includes:

  • Fig. S1. CD20 is not expressed in glomeruli from patients with recurrent FSGS.
  • Fig. S2. Generation of SMPDL-3b–overexpressing podocytes.
  • Fig. S3. Rituximab does not affect podocyte expression of vinculin, podocin, and nephrin.
  • Fig. S4. Disruption of the actin cytoskeleton does not affect SMPDL-3b in podocytes.
  • Fig. S5. Generation of SMPDL-3b knockdown podocytes.
  • Reference

[Download PDF]